Viral and Non-Viral Vector Manufacturing Market to Witness Massive Growth by 2031

A viral vector acts as the most efficient gene delivery tool that can be manipulated to express therapeutic genes. Currently, a wide range of viruses is effectively being used as vectors, including adenoviruses (AdV), retroviruses, lentivirus, poxviruses, adeno-associated viruses (AAV), baculoviruses, and herpes simplex viruses (HSV), among others. A virus is usually genetically modified prior to its use as vectors to make it more stable and less toxic and safe for administration. On the other hand, a plasmid is a small, extrachromosomal DNA molecule that can self-replicate independently from the host's chromosomal deoxyribonucleic acid (DNA). The ability to self-replicate and ease of modification have made plasmid an ideal gene delivery tool. Artificial plasmids, synthesized in the lab consisting of an origin of replication, selection marker, and cloning site, are also commonly used as vectors for successful gene delivery.

The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.

The global viral and non-viral vector manufacturing market is growing at a progressive rate, owning to the increasing application of vectors for the development of advanced therapies and the promising results displayed by them in preclinical and clinical studies of vector-based gene and cell therapies for the treatment of multiple diseases, starting from cancer to infectious diseases and genetic diseases. The increasing prevalence of cancer, cardiovascular diseases, genetic diseases, and infectious diseases, among others, is indirectly acting as the driving force, facilitating the high adoption of viral and non-viral vectors for the development of novel therapies. In order to meet the increasing demand for vectors, several vector manufacturing companies have expanded their manufacturing facilities and broadened their services/product portfolio in the past years. In addition, over the next few years, new diverse markets are expected to open, creating opportunities for a range of companies seeking to enter the field through product innovation while putting pressure on established vector manufacturers to reassess their operating models. Therefore, the market competition is expected to drive strategic business development activities, such as acquisitions, partnerships, joint-ventures, and collaborations, by key players.

Impact of COVID- 19 

The impact of the COVID-19 pandemic on the global viral and non-viral vector manufacturing market has been abrupt and drastic. Growing at an average growth rate of approximately , the global viral and non-viral vector manufacturing market is expected to witness a sudden drop in its growth rate between 2020 and 2021, as depicted in the preceding figure. However, the following years, post-2021, are expected to witness a surge in demand for vector-based cell and gene therapy products as well as vaccine products, along with a rise in clinical trial programs that are altogether expected to significantly contribute to the rapid growth of the market in the upcoming years. Further, increasing investment in biomanufacturing capacities and increasing partnerships and collaborations among key players of the biomanufacturing industry are also expected to propel the market growth of the viral and non-viral vector manufacturing market in the upcoming years. In contrast, in the absence of COVID-19, the market was originally expected to grow at a robust growth rate, attaining the maximum year-on-year (Y-o-Y) growth rate.

Competitive Landscape

The global viral and non-viral vector manufacturing market comprises well-established and newly emerging companies. Several companies are attempting to enter the market and sustain the competition by adopting synergistic activities and expanding their business by launching manufacturing capacities or developing proprietary viral and non-viral vector platforms.

In the past three years (2018-2020), the key market players of the global viral and non-viral vector manufacturing market witnessed majorly synergistic activities, business expansion, and funding activities. The inclination of companies toward synergies suggests that the companies are collaborating with viral and non-viral vector manufacturers to develop novel cell therapies, gene therapies, and vaccines for various diseases. The expansion of manufacturing capacities suggests that the companies are trying to fulfill the increased demand for vectors for cell and gene therapies.

Key Questions Answered in this Report:

•    What is a vector, and what is its importance in the medical industry? What are the major characteristics and types of vectors? What are the areas of application of vectors?
•    What are the major advancements in viral and non-viral vector manufacturing? What are the key trends of the global viral and non-viral vector manufacturing market? How is the market evolving, and what is its future scope?
•    What are the major drivers, challenges, and opportunities of the global viral and non-viral vector manufacturing market?
•    What are the key developmental strategies implemented by the key players of the global viral and non-viral vector manufacturing market to sustain the competition of the market? What is the percentage share of each of the key players in different key developmental strategies?
•    What is the regulatory scenario of the global viral and non-viral vector manufacturing market? What are the initiatives implemented by different governmental bodies and guidelines put forward to regulate the commercialization of viral and non-viral vector manufacturing products?
•    What are major milestones in patenting activity in the global viral and non-viral vector manufacturing market?
•    What was the market size of the global viral and non-viral vector manufacturing market in 2020, and what is the market size anticipated to be by 2031? What is the expected growth rate of the global viral and non-viral vector manufacturing market during the forecast period 2021-2031?
•    What is the global market size for manufacturing different types of viral and non-viral vectors available in the global viral and non-viral vector manufacturing market? What are the key trends of the market with respect to different vectors, and which vector type is expected to dominate the market in 2031?
•    What are the different disease areas where non-viral vectors and viral vectors are employed in the global viral and non-viral vector manufacturing market? Which disease type dominated the market in 2020 and is expected to dominate in 2031?
•    What are the different applications associated with the viral vector and non-viral vector manufacturing? What was the contribution of each of the application areas in the global viral and non-viral vector manufacturing market in 2020, and what is it expected in 2031?
•    Which region is expected to contribute the highest sales in the global viral and non-viral vector manufacturing market during the period 2021-2031? Which region and country carries the potential for the significant expansion of key companies for different viral and non-viral vector manufacturing? What are the leading countries of different regions that contribute significantly toward the growth of the viral and non-viral manufacturing market?
•    What are the key players of the global viral and non-viral vector manufacturing market, and what are their roles in the market? What were the market shares of the key players in 2020?

Request a Sample- https://bisresearch.com/requestsample?id=1205type=download

Within the research report, the market is segmented based on product type, end user, and regional analysis. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

BIS Related Studies-

Global Cell and Gene Therapy Market

Article source: https://article-realm.com/article/Finance/20116-Viral-and-Non-Viral-Vector-Manufacturing-Market-to-Witness-Massive-Growth-by-2031.html